Skip to main content
. 2020 Feb 12;34(2):183–196. doi: 10.1007/s40259-020-00406-1

Fig. 1.

Fig. 1

Patient disposition (all randomized patients). RTX-EU MabThera®, RTX-US Rituxan®. aThe number of patients analyzed for each outcome is presented in the electronic supplementary material, Table S5. bOne patient had primary reason for discontinuation as “B-cell recovery”; for this reason, the patient did not have all safety visits